Adherence Rates Low for Prostate Cancer Quality of Care Measures

Share this content:
Adherence Rates Low for Prostate Cancer Quality of Care Measures
Adherence Rates Low for Prostate Cancer Quality of Care Measures

(HealthDay News) — Adherence to established prostate cancer quality of care measures is frequently low, with considerable regional variation, according to a study published in the April issue of The Journal of Urology.

Florian R. Schroeck, MD, from the University of Michigan in Ann Arbor, and colleagues conducted a retrospective study to examine regional variation in adherence to quality measures for 53,614 patients with newly diagnosed prostate cancer. Patients were identified from Surveillance, Epidemiology, and End Results-Medicare data for 2001 to 2007, and were assigned to 661 regions.

RELATED: Surgery May Improve Survival in Younger Prostate Cancer Patients

The researchers observed extensive patient-level variation in adherence, varying from 33% for treatment by a high-volume provider to 76% for adjuvant androgen deprivation therapy receipt while undergoing radiation for high-risk cancer. 

Considerable regional variation was observed in adherence to several measures, including pretherapy counseling by a urologist and radiation oncologist, which ranged from 9% to 89%; avoiding bone scan overuse in low-risk cancer, which ranged from 16% to 96%; treatment by a high-volume provider, which ranged from 1% to 90%; and follow-up with a radiation oncologist, which varied from 14% to 86% (all P < 0.001).

"We found low adherence rates for most established prostate cancer quality of care measures. Within most measures regional variation in adherence was pronounced," the researchers wrote. "Measures with low adherence and a large amount of regional variation may be important low hanging targets for quality improvement."

One author disclosed financial ties to Amgen; one author disclosed financial ties to Elsevier.


  1. Schroeck FR, Kaufman SR, Jacobs BL, et al. Regional Variation in Quality of Prostate Cancer Care. J Urol. 2014;191(4):957–963.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs